Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), and End User– Global Forecast to 2024
The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out an impact analysis of the key industry drivers, restraints, opportunities, and challenges. The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market. However, high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.

Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five year survival rates as compared to other cancer treatment options available in market.

Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.

An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and Asia Pacific. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to development of bioinformatics. Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for growth of this market.

The key players profiled in the global cancer immunotherapy market research report are F. Hoffmann-La Roche, Celgene Corporation, Bristol-Myers Squibb, Merck & Co., Inc., Amgen Inc., ELI Lilly and Company, Janssen Global Services, LLC (Johnson and Johnson), Novartis, Pfizer, Inc., Gilead Sciences, Inc., Dendreon Pharmaceuticals, and Bayer among others.

Scope of the Report:
Market by Product

  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Immunomodulators
  • Vaccines
  • Cell Therapy

Market by Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Multiple Myeloma
  • Other Cancer Types

Market by End User

  • Hospitals
  • Clinics & Others

Market by Geography
North America

  • ·US
  • ·Canada


  • ·Germany
  • ·France
  • ·UK
  • ·Italy
  • ·Spain
  • ·Rest of Europe (RoE)

Asia-Pacific (APAC)

  • ·China
  • ·Japan
  • ·India
  • ·Rest of APAC (RoAPAC)

Latin America
Middle East & Africa